Cassava Sciences Inc. Faced with Securities Class Action Lawsuit
Radnor, Pa., Dec. 27, 2024 – Kessler Topaz Meltzer & Check, LLP has announced the filing of a securities class action lawsuit against Cassava Sciences Inc. (NASDAQ: SAVA) in the United States District Court for the Western District of Texas. The lawsuit alleges that Cassava made misleading statements and failed to disclose critical information about the effectiveness of their drug, simufilam, in treating Alzheimer’s Disease.
Case Overview
The lawsuit seeks to represent investors who purchased or acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive. Investors have until February 10, 2025, to file motions to serve as the lead plaintiff.
Contact Information
If you believe you have suffered losses due to these alleged misstatements, you can contact Kessler Topaz Meltzer & Check, LLP for more information:
- Visit their website: https://www.ktmc.com/new-cases/cassava-sciences-inc-2024?utm_source=PR&utm_medium=link&utm_campaign=sava&mktm=r
- Email attorney Jonathan Naji: info@ktmc.com
- Call: (484) 270-1453
Alleged Misconduct
The complaint alleges that Cassava made false and misleading statements about the effectiveness of simufilam in treating Alzheimer’s Disease. Specifically, the company allegedly represented that the drug could abate the progression of the disease, even in mild to moderate cases. However, according to the lawsuit, this claim was not supported by adequate evidence, leading to materially false and misleading statements about the company’s business, operations, and prospects.
Lead Plaintiff Process
Cassava investors interested in potentially serving as the lead plaintiff must file motions with the court by February 10, 2025. The lead plaintiff will represent all class members in the litigation. Typically, this role is filled by investors with the largest financial interest in the case who are also considered typical of the class. The lead plaintiff selects and oversees the legal team representing the class in court. Notably, an individual’s ability to share in any recovery is not dependent on whether they become the lead plaintiff.
Prospective Investors’ Action Plan
Investors who are concerned about potential losses and wish to pursue legal action against Cassava Sciences Inc. are encouraged to contact Kessler Topaz Meltzer & Check, LLP for further information and guidance. The firm specializes in representing victims of corporate misconduct and has a proven track record in recovering significant compensation.
For more information or to sign up for the case, visit this page on the firm’s website.
About Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP is a prominent law firm known for its work in class action litigation. With offices nationwide, the firm has successfully pursued numerous cases involving corporate fraud and misconduct, recovering billions of dollars for affected individuals and entities. The firm’s commitment to ethical and effective representation has earned it a reputation for excellence in the legal community.
The complaint in this case was not filed by Kessler Topaz Meltzer & Check, LLP. Visit their official website at www.ktmc.com for more information on their services and current cases.
Contact Information
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
info@ktmc.com
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Stay informed about the latest developments in investor protection and corporate litigation. Share your thoughts in the comments below or subscribe to our newsletter for regular updates. Don’t forget to share this article on social media to help others understand their rights.
